 Jennifer Kiser
Concepts (348)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antiviral Agents | 30 | 2023 | 645 | 6.420 |
Why?
| | Anti-HIV Agents | 32 | 2023 | 666 | 4.530 |
Why?
| | HIV Infections | 53 | 2023 | 2469 | 4.440 |
Why?
| | Hepatitis C | 13 | 2023 | 219 | 4.390 |
Why?
| | Adenine | 27 | 2022 | 219 | 4.000 |
Why?
| | Hepatitis C, Chronic | 13 | 2023 | 151 | 3.900 |
Why?
| | Ribavirin | 15 | 2020 | 89 | 3.890 |
Why?
| | Sofosbuvir | 12 | 2023 | 54 | 3.600 |
Why?
| | Drug Interactions | 21 | 2019 | 338 | 3.430 |
Why?
| | Tenofovir | 28 | 2022 | 204 | 3.020 |
Why?
| | Tandem Mass Spectrometry | 16 | 2023 | 412 | 2.470 |
Why?
| | Hepacivirus | 10 | 2023 | 229 | 1.980 |
Why?
| | Proline | 5 | 2019 | 72 | 1.950 |
Why?
| | Oligopeptides | 8 | 2015 | 236 | 1.860 |
Why?
| | Dried Blood Spot Testing | 12 | 2023 | 71 | 1.770 |
Why?
| | Organophosphates | 13 | 2022 | 90 | 1.750 |
Why?
| | Organophosphonates | 12 | 2014 | 90 | 1.620 |
Why?
| | Ritonavir | 8 | 2021 | 71 | 1.490 |
Why?
| | Protease Inhibitors | 4 | 2020 | 97 | 1.450 |
Why?
| | Emtricitabine | 17 | 2021 | 147 | 1.390 |
Why?
| | Chromatography, Liquid | 13 | 2023 | 347 | 1.330 |
Why?
| | Phosphorous Acids | 3 | 2019 | 12 | 1.240 |
Why?
| | Benzimidazoles | 5 | 2020 | 138 | 1.230 |
Why?
| | Coinfection | 4 | 2018 | 120 | 1.160 |
Why?
| | Fluorenes | 4 | 2020 | 38 | 1.130 |
Why?
| | Pyrophosphatases | 3 | 2016 | 22 | 1.110 |
Why?
| | Nucleotides | 3 | 2016 | 112 | 1.100 |
Why?
| | Medication Adherence | 16 | 2022 | 536 | 1.000 |
Why?
| | Anti-Retroviral Agents | 5 | 2019 | 207 | 0.980 |
Why?
| | Drug Therapy, Combination | 11 | 2018 | 951 | 0.900 |
Why?
| | Hepatitis B | 3 | 2022 | 51 | 0.880 |
Why?
| | Pyridines | 5 | 2015 | 425 | 0.880 |
Why?
| | Erythrocytes | 8 | 2016 | 591 | 0.840 |
Why?
| | Humans | 96 | 2023 | 114696 | 0.840 |
Why?
| | Polyphosphates | 7 | 2022 | 33 | 0.800 |
Why?
| | Cell Phone | 1 | 2022 | 76 | 0.780 |
Why?
| | Reverse Transcriptase Inhibitors | 5 | 2014 | 82 | 0.770 |
Why?
| | HIV Protease Inhibitors | 5 | 2011 | 64 | 0.770 |
Why?
| | HIV-1 | 7 | 2021 | 768 | 0.750 |
Why?
| | Membrane Transport Proteins | 4 | 2016 | 138 | 0.750 |
Why?
| | Sulfonamides | 5 | 2019 | 445 | 0.740 |
Why?
| | Simeprevir | 2 | 2018 | 8 | 0.740 |
Why?
| | Mobile Applications | 1 | 2022 | 141 | 0.710 |
Why?
| | Therapies, Investigational | 1 | 2019 | 14 | 0.670 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2020 | 97 | 0.650 |
Why?
| | Heterocyclic Compounds, 3-Ring | 2 | 2023 | 28 | 0.640 |
Why?
| | Male | 51 | 2023 | 55604 | 0.640 |
Why?
| | Ethanol | 1 | 2023 | 538 | 0.630 |
Why?
| | Adult | 40 | 2021 | 30552 | 0.630 |
Why?
| | Middle Aged | 35 | 2020 | 26737 | 0.620 |
Why?
| | Lung Transplantation | 1 | 2020 | 246 | 0.610 |
Why?
| | Pyridazines | 2 | 2021 | 46 | 0.600 |
Why?
| | Antiretroviral Therapy, Highly Active | 4 | 2015 | 256 | 0.590 |
Why?
| | Liver | 2 | 2016 | 1637 | 0.580 |
Why?
| | Leukocytes, Mononuclear | 8 | 2021 | 493 | 0.580 |
Why?
| | Solid Phase Extraction | 2 | 2014 | 20 | 0.580 |
Why?
| | Pyrimidinones | 2 | 2008 | 88 | 0.560 |
Why?
| | Viral Load | 10 | 2023 | 405 | 0.550 |
Why?
| | HIV Integrase Inhibitors | 1 | 2018 | 62 | 0.550 |
Why?
| | Inosine | 1 | 2016 | 11 | 0.540 |
Why?
| | Guanosine | 1 | 2016 | 39 | 0.540 |
Why?
| | Pharmacogenomic Variants | 1 | 2016 | 33 | 0.530 |
Why?
| | Female | 45 | 2023 | 59518 | 0.520 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2015 | 470 | 0.520 |
Why?
| | Purines | 1 | 2016 | 159 | 0.510 |
Why?
| | Kidney | 4 | 2016 | 1188 | 0.500 |
Why?
| | Drug Monitoring | 3 | 2022 | 184 | 0.500 |
Why?
| | Drug Discovery | 1 | 2016 | 123 | 0.500 |
Why?
| | Isoniazid | 2 | 2012 | 52 | 0.490 |
Why?
| | Serum | 1 | 2015 | 57 | 0.480 |
Why?
| | Adenosine | 1 | 2016 | 203 | 0.480 |
Why?
| | Intracellular Space | 1 | 2014 | 68 | 0.470 |
Why?
| | Telemedicine | 1 | 2022 | 662 | 0.470 |
Why?
| | Pre-Exposure Prophylaxis | 5 | 2020 | 179 | 0.460 |
Why?
| | HIV | 4 | 2019 | 208 | 0.450 |
Why?
| | Antitubercular Agents | 2 | 2012 | 169 | 0.450 |
Why?
| | Deoxycytidine | 6 | 2017 | 138 | 0.450 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 2013 | 28 | 0.440 |
Why?
| | Priapism | 1 | 2013 | 10 | 0.440 |
Why?
| | Adrenergic alpha-Antagonists | 1 | 2013 | 29 | 0.440 |
Why?
| | Cytochrome P-450 CYP3A Inhibitors | 1 | 2013 | 18 | 0.440 |
Why?
| | Gastric Bypass | 1 | 2014 | 92 | 0.410 |
Why?
| | Hepatitis B, Chronic | 3 | 2022 | 18 | 0.410 |
Why?
| | Treatment Outcome | 12 | 2021 | 9088 | 0.410 |
Why?
| | Prospective Studies | 17 | 2022 | 6220 | 0.390 |
Why?
| | Phenotype | 2 | 2016 | 2796 | 0.390 |
Why?
| | Pyrimidines | 3 | 2021 | 376 | 0.370 |
Why?
| | HIV Seronegativity | 1 | 2010 | 24 | 0.360 |
Why?
| | Genotype | 6 | 2023 | 1760 | 0.360 |
Why?
| | Antacids | 1 | 2010 | 15 | 0.360 |
Why?
| | Pyrrolidinones | 1 | 2010 | 25 | 0.360 |
Why?
| | Patient Compliance | 3 | 2017 | 525 | 0.350 |
Why?
| | Hepatitis B virus | 3 | 2022 | 25 | 0.350 |
Why?
| | Tuberculosis | 2 | 2012 | 241 | 0.350 |
Why?
| | Pharmacy Service, Hospital | 1 | 2011 | 83 | 0.350 |
Why?
| | Reproducibility of Results | 8 | 2016 | 2765 | 0.340 |
Why?
| | Blood Chemical Analysis | 4 | 2019 | 90 | 0.330 |
Why?
| | Plasma | 4 | 2016 | 211 | 0.330 |
Why?
| | Area Under Curve | 4 | 2018 | 274 | 0.330 |
Why?
| | Adolescent | 19 | 2020 | 17853 | 0.320 |
Why?
| | Uridine Monophosphate | 2 | 2019 | 15 | 0.320 |
Why?
| | Drug Prescriptions | 1 | 2011 | 239 | 0.320 |
Why?
| | Young Adult | 16 | 2020 | 10471 | 0.310 |
Why?
| | Fluorobenzenes | 1 | 2008 | 11 | 0.300 |
Why?
| | Drug Stability | 5 | 2016 | 151 | 0.290 |
Why?
| | Guidelines as Topic | 1 | 2009 | 243 | 0.290 |
Why?
| | Liver Transplantation | 1 | 2014 | 707 | 0.290 |
Why?
| | Sensitivity and Specificity | 5 | 2014 | 1693 | 0.280 |
Why?
| | Atazanavir Sulfate | 5 | 2015 | 41 | 0.280 |
Why?
| | Half-Life | 3 | 2015 | 141 | 0.270 |
Why?
| | Glycerophospholipids | 2 | 2023 | 26 | 0.270 |
Why?
| | Alanine | 3 | 2021 | 104 | 0.270 |
Why?
| | Esomeprazole | 1 | 2006 | 6 | 0.260 |
Why?
| | Anti-Ulcer Agents | 1 | 2006 | 16 | 0.260 |
Why?
| | Pharmacology, Clinical | 1 | 2006 | 8 | 0.260 |
Why?
| | Carbamates | 1 | 2006 | 34 | 0.260 |
Why?
| | Sustained Virologic Response | 3 | 2023 | 33 | 0.260 |
Why?
| | Hepatocytes | 3 | 2016 | 195 | 0.260 |
Why?
| | Education | 1 | 2006 | 95 | 0.250 |
Why?
| | Biomarkers | 5 | 2023 | 3408 | 0.250 |
Why?
| | Proton Pump Inhibitors | 1 | 2006 | 96 | 0.240 |
Why?
| | South Africa | 4 | 2015 | 161 | 0.240 |
Why?
| | Phosphates | 3 | 2015 | 159 | 0.230 |
Why?
| | Anemia | 2 | 2016 | 143 | 0.230 |
Why?
| | Health Personnel | 1 | 2009 | 574 | 0.220 |
Why?
| | Variola virus | 1 | 2022 | 1 | 0.210 |
Why?
| | Smallpox | 1 | 2022 | 7 | 0.210 |
Why?
| | Delivery of Health Care | 1 | 2009 | 833 | 0.200 |
Why?
| | Cross-Over Studies | 4 | 2020 | 440 | 0.200 |
Why?
| | World Health Organization | 1 | 2022 | 102 | 0.200 |
Why?
| | Linear Models | 2 | 2014 | 768 | 0.190 |
Why?
| | Cyclopropanes | 2 | 2019 | 81 | 0.190 |
Why?
| | Point-of-Care Systems | 1 | 2023 | 136 | 0.190 |
Why?
| | Lopinavir | 3 | 2020 | 29 | 0.190 |
Why?
| | Dideoxynucleosides | 2 | 2023 | 20 | 0.190 |
Why?
| | Interferons | 2 | 2019 | 151 | 0.180 |
Why?
| | Phosphorylation | 2 | 2015 | 1569 | 0.180 |
Why?
| | Drug Administration Schedule | 3 | 2019 | 718 | 0.170 |
Why?
| | Aminoisobutyric Acids | 1 | 2019 | 7 | 0.170 |
Why?
| | Lactams, Macrocyclic | 1 | 2019 | 46 | 0.160 |
Why?
| | Pyrrolidines | 1 | 2019 | 55 | 0.160 |
Why?
| | Homosexuality, Male | 2 | 2017 | 170 | 0.160 |
Why?
| | Quinoxalines | 1 | 2019 | 60 | 0.160 |
Why?
| | Leucine | 1 | 2019 | 102 | 0.160 |
Why?
| | Nucleic Acids | 1 | 2019 | 59 | 0.160 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2020 | 288 | 0.160 |
Why?
| | Quality Control | 2 | 2015 | 144 | 0.150 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2020 | 590 | 0.150 |
Why?
| | Organic Anion Transport Protein 1 | 2 | 2008 | 6 | 0.150 |
Why?
| | Oxazines | 1 | 2018 | 25 | 0.150 |
Why?
| | Multidrug Resistance-Associated Proteins | 2 | 2008 | 34 | 0.150 |
Why?
| | Liver Cirrhosis | 1 | 2019 | 227 | 0.150 |
Why?
| | Directly Observed Therapy | 1 | 2017 | 14 | 0.150 |
Why?
| | Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | 1 | 2017 | 14 | 0.150 |
Why?
| | Pregnancy Outcome | 1 | 2020 | 337 | 0.140 |
Why?
| | Nitriles | 2 | 2021 | 149 | 0.140 |
Why?
| | Pharmacogenetics | 2 | 2016 | 149 | 0.140 |
Why?
| | Inosine Triphosphate | 1 | 2016 | 3 | 0.140 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 347 | 0.140 |
Why?
| | Anemia, Hemolytic | 1 | 2016 | 18 | 0.140 |
Why?
| | Darunavir | 2 | 2014 | 17 | 0.140 |
Why?
| | Zika Virus | 1 | 2017 | 61 | 0.140 |
Why?
| | Deoxyadenine Nucleotides | 1 | 2016 | 13 | 0.140 |
Why?
| | Deoxycytosine Nucleotides | 1 | 2016 | 11 | 0.140 |
Why?
| | Pharmacy | 1 | 2017 | 28 | 0.140 |
Why?
| | Pyridones | 1 | 2018 | 123 | 0.140 |
Why?
| | Guanosine Triphosphate | 1 | 2016 | 85 | 0.140 |
Why?
| | Glass | 1 | 2016 | 42 | 0.140 |
Why?
| | Retrospective Studies | 4 | 2020 | 12554 | 0.130 |
Why?
| | Genitalia | 1 | 2016 | 28 | 0.130 |
Why?
| | Disease Transmission, Infectious | 1 | 2017 | 55 | 0.130 |
Why?
| | Syringes | 1 | 2016 | 41 | 0.130 |
Why?
| | Viremia | 3 | 2022 | 122 | 0.130 |
Why?
| | Drug Packaging | 1 | 2016 | 42 | 0.130 |
Why?
| | Drug and Narcotic Control | 1 | 2016 | 29 | 0.130 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2011 | 373 | 0.130 |
Why?
| | Polymers | 1 | 2019 | 448 | 0.130 |
Why?
| | Fibroblast Growth Factors | 2 | 2014 | 162 | 0.130 |
Why?
| | Mental Health Services | 1 | 2019 | 317 | 0.130 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1395 | 0.130 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2016 | 1880 | 0.130 |
Why?
| | Creatinine | 2 | 2018 | 425 | 0.130 |
Why?
| | Piperazines | 1 | 2018 | 309 | 0.130 |
Why?
| | Analgesics | 1 | 2017 | 158 | 0.130 |
Why?
| | Rectum | 1 | 2016 | 153 | 0.120 |
Why?
| | Biological Assay | 1 | 2016 | 112 | 0.120 |
Why?
| | Cytosol | 1 | 2016 | 208 | 0.120 |
Why?
| | Virus Replication | 1 | 2017 | 395 | 0.120 |
Why?
| | Brain Diseases | 1 | 2016 | 125 | 0.120 |
Why?
| | Population | 1 | 2015 | 28 | 0.120 |
Why?
| | Nonlinear Dynamics | 1 | 2015 | 83 | 0.120 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2016 | 125 | 0.120 |
Why?
| | Infant | 5 | 2020 | 7964 | 0.120 |
Why?
| | Liver Function Tests | 1 | 2015 | 103 | 0.120 |
Why?
| | Pharmacists | 1 | 2017 | 233 | 0.120 |
Why?
| | CD4 Lymphocyte Count | 2 | 2015 | 257 | 0.120 |
Why?
| | Adenosine Triphosphate | 1 | 2016 | 430 | 0.120 |
Why?
| | Administration, Oral | 3 | 2019 | 728 | 0.120 |
Why?
| | Pharmaceutical Preparations | 1 | 2016 | 165 | 0.110 |
Why?
| | Least-Squares Analysis | 1 | 2014 | 70 | 0.110 |
Why?
| | Double-Blind Method | 3 | 2013 | 1660 | 0.110 |
Why?
| | Metabolic Clearance Rate | 2 | 2018 | 102 | 0.110 |
Why?
| | Hypophosphatemia | 1 | 2013 | 15 | 0.110 |
Why?
| | Cholecalciferol | 1 | 2014 | 47 | 0.110 |
Why?
| | Liver Diseases | 1 | 2016 | 255 | 0.110 |
Why?
| | Diphosphates | 3 | 2021 | 16 | 0.110 |
Why?
| | Calcitriol | 1 | 2013 | 53 | 0.110 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2013 | 61 | 0.110 |
Why?
| | Leukocytes | 1 | 2014 | 276 | 0.110 |
Why?
| | Tablets | 2 | 2023 | 36 | 0.110 |
Why?
| | Child, Preschool | 4 | 2021 | 9118 | 0.100 |
Why?
| | Desiccation | 1 | 2012 | 17 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 900 | 0.100 |
Why?
| | Kidney Diseases | 1 | 2016 | 350 | 0.100 |
Why?
| | Monocytes | 1 | 2015 | 504 | 0.100 |
Why?
| | Benzoxazines | 1 | 2012 | 28 | 0.100 |
Why?
| | Organic Anion Transporters | 1 | 2011 | 15 | 0.100 |
Why?
| | Pravastatin | 1 | 2011 | 28 | 0.100 |
Why?
| | Levonorgestrel | 1 | 2012 | 31 | 0.100 |
Why?
| | Mental Disorders | 1 | 2019 | 893 | 0.100 |
Why?
| | Vitamin D Deficiency | 1 | 2013 | 158 | 0.100 |
Why?
| | Arylamine N-Acetyltransferase | 1 | 2011 | 5 | 0.090 |
Why?
| | Specimen Handling | 1 | 2012 | 155 | 0.090 |
Why?
| | Interferon-alpha | 1 | 2012 | 186 | 0.090 |
Why?
| | Nucleosides | 1 | 2011 | 25 | 0.090 |
Why?
| | Contraceptive Agents, Female | 1 | 2012 | 64 | 0.090 |
Why?
| | Models, Statistical | 1 | 2015 | 599 | 0.090 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 681 | 0.090 |
Why?
| | Aged | 4 | 2018 | 19074 | 0.090 |
Why?
| | Raltegravir Potassium | 1 | 2010 | 16 | 0.090 |
Why?
| | Body Weight | 1 | 2015 | 869 | 0.090 |
Why?
| | Hospitals, University | 1 | 2011 | 172 | 0.090 |
Why?
| | Cohort Studies | 2 | 2019 | 4895 | 0.090 |
Why?
| | Sex Characteristics | 1 | 2015 | 641 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2014 | 460 | 0.090 |
Why?
| | Sex Distribution | 1 | 2011 | 337 | 0.090 |
Why?
| | Mycobacterium tuberculosis | 1 | 2012 | 268 | 0.080 |
Why?
| | Time Factors | 4 | 2016 | 6116 | 0.080 |
Why?
| | Drug Combinations | 2 | 2020 | 287 | 0.080 |
Why?
| | Lamivudine | 2 | 2023 | 59 | 0.080 |
Why?
| | Rosuvastatin Calcium | 1 | 2008 | 17 | 0.080 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 646 | 0.070 |
Why?
| | Case-Control Studies | 2 | 2020 | 3003 | 0.070 |
Why?
| | Kidney Calculi | 1 | 2007 | 30 | 0.070 |
Why?
| | Gene Frequency | 1 | 2008 | 477 | 0.070 |
Why?
| | Portugal | 1 | 2006 | 9 | 0.070 |
Why?
| | Education, Medical | 1 | 2009 | 215 | 0.070 |
Why?
| | Self Report | 2 | 2021 | 696 | 0.070 |
Why?
| | Dementia | 1 | 2009 | 187 | 0.070 |
Why?
| | Quebec | 1 | 2006 | 5 | 0.070 |
Why?
| | Referral and Consultation | 1 | 2011 | 635 | 0.070 |
Why?
| | Furans | 1 | 2006 | 22 | 0.070 |
Why?
| | Sexual and Gender Minorities | 2 | 2019 | 138 | 0.060 |
Why?
| | United States | 4 | 2017 | 12185 | 0.060 |
Why?
| | Child | 4 | 2021 | 18420 | 0.060 |
Why?
| | Internationality | 1 | 2006 | 143 | 0.060 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2020 | 152 | 0.060 |
Why?
| | Hematocrit | 2 | 2016 | 87 | 0.060 |
Why?
| | Lipids | 1 | 2008 | 580 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2019 | 1796 | 0.060 |
Why?
| | Risk Assessment | 1 | 2012 | 2968 | 0.050 |
Why?
| | Isoindoles | 1 | 2022 | 4 | 0.050 |
Why?
| | Monkeypox virus | 1 | 2022 | 12 | 0.050 |
Why?
| | Animals | 4 | 2022 | 31708 | 0.050 |
Why?
| | Calibration | 2 | 2013 | 125 | 0.050 |
Why?
| | Computer Simulation | 2 | 2016 | 873 | 0.050 |
Why?
| | Temperature | 2 | 2016 | 565 | 0.050 |
Why?
| | Benzamides | 1 | 2022 | 169 | 0.050 |
Why?
| | Pregnancy | 3 | 2020 | 5520 | 0.050 |
Why?
| | Demography | 1 | 2022 | 260 | 0.050 |
Why?
| | Treatment Failure | 1 | 2023 | 331 | 0.050 |
Why?
| | Tissue Donors | 1 | 2023 | 316 | 0.040 |
Why?
| | Drug Approval | 1 | 2020 | 78 | 0.040 |
Why?
| | Lactation | 1 | 2020 | 149 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 1842 | 0.040 |
Why?
| | Benchmarking | 1 | 2020 | 161 | 0.040 |
Why?
| | Models, Biological | 2 | 2016 | 1621 | 0.040 |
Why?
| | Developing Countries | 1 | 2020 | 235 | 0.040 |
Why?
| | Chemistry Techniques, Analytical | 1 | 2018 | 18 | 0.040 |
Why?
| | Flaviviridae | 1 | 2017 | 4 | 0.040 |
Why?
| | Drug Repositioning | 1 | 2017 | 13 | 0.040 |
Why?
| | Hair | 1 | 2018 | 65 | 0.040 |
Why?
| | Vero Cells | 1 | 2017 | 63 | 0.040 |
Why?
| | A549 Cells | 1 | 2017 | 51 | 0.040 |
Why?
| | Inhibitory Concentration 50 | 1 | 2017 | 74 | 0.040 |
Why?
| | Alcohol Drinking | 1 | 2023 | 651 | 0.040 |
Why?
| | Breast Feeding | 1 | 2020 | 368 | 0.040 |
Why?
| | Patient Selection | 1 | 2020 | 641 | 0.030 |
Why?
| | Pharmaceutical Solutions | 1 | 2016 | 14 | 0.030 |
Why?
| | Cities | 1 | 2017 | 80 | 0.030 |
Why?
| | Chromatography, Reverse-Phase | 1 | 2016 | 26 | 0.030 |
Why?
| | Acute Disease | 1 | 2019 | 911 | 0.030 |
Why?
| | Drug Storage | 1 | 2016 | 58 | 0.030 |
Why?
| | Defective Viruses | 1 | 2016 | 4 | 0.030 |
Why?
| | Drug Compounding | 1 | 2016 | 89 | 0.030 |
Why?
| | Solubility | 1 | 2016 | 223 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 932 | 0.030 |
Why?
| | Spermatozoa | 1 | 2016 | 84 | 0.030 |
Why?
| | Methanol | 1 | 2016 | 29 | 0.030 |
Why?
| | Cold Temperature | 1 | 2016 | 126 | 0.030 |
Why?
| | Blood-Brain Barrier | 1 | 2016 | 106 | 0.030 |
Why?
| | Solutions | 1 | 2016 | 146 | 0.030 |
Why?
| | Pregnancy Complications | 1 | 2020 | 429 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2016 | 511 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1448 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2016 | 641 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 1841 | 0.030 |
Why?
| | Risk-Taking | 1 | 2017 | 333 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2017 | 740 | 0.030 |
Why?
| | Mental Health | 1 | 2019 | 562 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 935 | 0.030 |
Why?
| | Interleukins | 1 | 2016 | 236 | 0.030 |
Why?
| | DNA, Viral | 1 | 2016 | 350 | 0.030 |
Why?
| | Vitamin D-Binding Protein | 1 | 2013 | 13 | 0.030 |
Why?
| | Algorithms | 1 | 2020 | 1469 | 0.030 |
Why?
| | Parathyroid Hormone | 1 | 2013 | 96 | 0.030 |
Why?
| | Water | 1 | 2016 | 396 | 0.030 |
Why?
| | Therapeutic Equivalency | 1 | 2012 | 18 | 0.020 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 238 | 0.020 |
Why?
| | Cell Line | 1 | 2017 | 2637 | 0.020 |
Why?
| | Alkynes | 1 | 2012 | 53 | 0.020 |
Why?
| | Anion Exchange Resins | 1 | 2011 | 7 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2387 | 0.020 |
Why?
| | Zidovudine | 1 | 2011 | 77 | 0.020 |
Why?
| | Food-Drug Interactions | 1 | 2010 | 6 | 0.020 |
Why?
| | Reference Standards | 1 | 2011 | 159 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2016 | 951 | 0.020 |
Why?
| | Chemoprevention | 1 | 2010 | 88 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2013 | 604 | 0.020 |
Why?
| | Latent Tuberculosis | 1 | 2011 | 64 | 0.020 |
Why?
| | Haplotypes | 1 | 2011 | 448 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2020 | 5047 | 0.020 |
Why?
| | Cholesterol | 1 | 2011 | 367 | 0.020 |
Why?
| | Triglycerides | 1 | 2011 | 467 | 0.020 |
Why?
| | AIDS Dementia Complex | 1 | 2009 | 50 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 4410 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4411 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2011 | 610 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 259 | 0.020 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2009 | 217 | 0.020 |
Why?
| | Calcium | 1 | 2013 | 1108 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2320 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 6347 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2009 | 927 | 0.010 |
Why?
| | Brain | 1 | 2016 | 2371 | 0.010 |
Why?
| | Age Factors | 1 | 2011 | 2894 | 0.010 |
Why?
| | Alzheimer Disease | 1 | 2009 | 442 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2009 | 3053 | 0.010 |
Why?
|
|
Kiser's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|